Category: 2092807-41-3

On April 2, 2021, Fang, Wenkui; Li, Guanqun; Cai, Yuting; Pan, Xiang; Zhu, Wenhao; Wang, Yang; Wang, Zengquan published a patent.Quality Control of 6,8-Dichloro-[1,2,4]triazolo[1,5-a]pyrazine The title of the patent was Preparation of triazolopyrazine compound as Tyk2 specific inhibitor for prevention and/or treatment of autoimmune diseases and related inflammatory skin diseases. And the patent contained the following:

The present invention relates to the preparation of triazolopyrazine compound as Tyk2 specific inhibitor for prevention and/or treatment of autoimmune diseases and related inflammatory skin diseases. In particular, the triazole pyrazine compound I (wherein, W = (un)substituted aryl or heteroaryl; X = C or N; R = H or any substituent group such as halogen, cyanide, amino, alkyl, alkoxy, cyanoalkyl etc) or its stereoisomers, geometric isomers, tautomers, hydrates, solvates and pharmaceutically acceptable salts or prodrugs were prepared The inventive compound can be used as a Tyk2 specific inhibitor which can provide a more targeted medicament for an autoimmune inflammatory disease driven by an IL-23/Th17 axis and diseases such as rheumatoid arthritis, psoriasis, compulsive spondylitis, Sjogren’s syndrome, lupus erythematosus, inflammatory bowel disease, Behcet’s disease, Covid-19 severe pneumonia can be safely and effectively treated. The experimental process involved the reaction of 6,8-Dichloro-[1,2,4]triazolo[1,5-a]pyrazine(cas: 2092807-41-3).Quality Control of 6,8-Dichloro-[1,2,4]triazolo[1,5-a]pyrazine

The Article related to triazolopyrazine compound preparation tyk2 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 6,8-Dichloro-[1,2,4]triazolo[1,5-a]pyrazine

Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics

On June 16, 2022, Fang, Wenkui; Li, Guanqun; Cai, Yuting; Pan, Xiang; Zhu, Wenhao; Wang, Yang; Wang, Zengquan published a patent.Electric Literature of 2092807-41-3 The title of the patent was Preparation of triazolopyrazine compound as Tyk2 specific inhibitor for prevention and/or treatment of autoimmune diseases and related inflammatory skin diseases. And the patent contained the following:

A triazolo pyrazine compound, wherein the triazolo pyrazine compound is a compound as represented by formula I as follows, or a stereoisomer, a geometrical isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodrug thereof, wherein W is selected from a substituted or unsubstituted aryl or heteroaryl, X is C or N, and R is H or any substituent group. When the triazolo pyrazine compound provided by the invention is used as a Tyk2 specific inhibitor, a more targeted drug can be provided for autoimmune inflammatory diseases driven by an IL-23/Th17 axis, and the compound can be used for treating rheumatoid arthritis, psoriasis, ankylosing spondylitis, sicca syndrome, lupus erythematosus, inflammatory bowel disease, Behcet’s disease, severe COVID-19 pneumonia and other diseases more safely and effectively. The experimental process involved the reaction of 6,8-Dichloro-[1,2,4]triazolo[1,5-a]pyrazine(cas: 2092807-41-3).Electric Literature of 2092807-41-3

The Article related to triazolopyrazine compound preparation tyk2 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 2092807-41-3

Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics